2022
Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials
Khairani C, Bejjani A, Piazza G, Jimenez D, Monreal M, Chatterjee S, Pengo V, Woller S, Cortes-Hernandez J, Connors J, Kanthi Y, Krumholz H, Middeldorp S, Falanga A, Cushman M, Goldhaber S, Garcia D, Bikdeli B. Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes Meta-Analysis of Randomized Trials. Journal Of The American College Of Cardiology 2022, 81: 16-30. PMID: 36328154, PMCID: PMC9812926, DOI: 10.1016/j.jacc.2022.10.008.Peer-Reviewed Original ResearchConceptsDirect oral anticoagulantsVitamin K antagonistsVenous thromboembolic eventsArterial thrombotic eventsSubsequent venous thromboembolic eventsThrombotic antiphospholipid syndromeMajor bleedingThrombotic eventsK antagonistsOral anticoagulantsAntiphospholipid syndromeUse of DOACsMain efficacy outcomeMain safety outcomeCochrane Central RegisterAdequate allocation concealmentRandom-effects modelRandom sequence generationThromboembolic eventsCentral RegisterEfficacy outcomesArterial thrombosisControlled TrialsRandomized trialsAllocation concealment
2020
Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials
Bikdeli B, Chatterjee S, Kirtane AJ, Parikh SA, Andreozzi GM, Desai NR, Francese DP, Gibson CM, Piazza G, Goldhaber SZ, Eikelboom JW, Krumholz HM, Stone GW. Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials. Seminars In Thrombosis And Hemostasis 2020, 46: 908-918. PMID: 33086402, DOI: 10.1055/s-0040-1716874.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisUse of sulodexideCause mortalityCardiovascular mortalityReduced oddsPulmonary embolismOdds ratioOdds of VTESafety of sulodexideCardiovascular risk factorsCochrane Central RegisterPeripheral arterial diseaseHistory of MIThrombotic cardiovascular diseasesRandom-effects modelCardiovascular efficacyOral glycosaminoglycansCardiovascular outcomesHemorrhagic eventsCentral RegisterVein thrombosisControlled TrialsArterial diseaseRandomized trialsRisk factorsUpdating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, Bracken MB, Desai M, Krumholz HM, Ross JS. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. The BMJ 2020, 368: l7078. PMID: 32024657, PMCID: PMC7190063, DOI: 10.1136/bmj.l7078.Peer-Reviewed Original ResearchConceptsIndividual patient-level dataCardiovascular related deathsCardiovascular riskMyocardial infarctionRelated deathsSummary-level dataHeart failureOdds ratioSystematic reviewIncreased cardiovascular riskMore myocardial infarctionsHeart failure eventsCochrane Central RegistryAcute myocardial infarctionMyocardial infarction eventsPatient-level dataRandom-effects modelWeb of ScienceAnalysis of trialsEligible trialsComposite outcomeAdverse eventsContinuity correctionControlled TrialsRosiglitazone treatment
2017
Inferior Vena Cava Filters to Prevent Pulmonary Embolism Systematic Review and Meta-Analysis
Bikdeli B, Chatterjee S, Desai NR, Kirtane AJ, Desai MM, Bracken MB, Spencer FA, Monreal M, Goldhaber SZ, Krumholz HM. Inferior Vena Cava Filters to Prevent Pulmonary Embolism Systematic Review and Meta-Analysis. Journal Of The American College Of Cardiology 2017, 70: 1587-1597. PMID: 28935036, PMCID: PMC8412839, DOI: 10.1016/j.jacc.2017.07.775.Peer-Reviewed Original ResearchConceptsDeep vein thrombosisSubsequent pulmonary embolismInferior vena cava filterPulmonary embolismVena cava filtersIVC filtersCause mortalityOdds ratioCava filtersSystematic reviewSubsequent deep vein thrombosisInverse variance fixed-effect modelRisk of PECochrane Central RegisterQuality of evidenceFixed-effects modelCentral RegisterVein thrombosisControlled TrialsOverall mortalityObservational studyMAIN OUTCOMEPrimary analysisMeta-AnalysisMortality
2006
Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease
Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of Renal Disease in Randomized Controlled Trials of Cardiovascular Disease. JAMA 2006, 296: 1377-1384. PMID: 16985230, DOI: 10.1001/jama.296.11.1377.Peer-Reviewed Original ResearchConceptsChronic congestive heart failureCongestive heart failureRenal diseaseRenal functionHeart failureSubgroup analysisCardiovascular diseaseCardiology/American Heart Association guidelinesAmerican Heart Association guidelinesAldosterone system antagonistsBaseline renal functionHeart Association guidelinesCardiovascular disease trialsCurrent American CollegeRandomized Controlled TrialsAcute myocardial infarctionEffects of interventionsRepresentation of patientsOriginal articlesBaseline characteristicsCardiovascular mortalityPatient characteristicsControlled TrialsPrognostic featuresMyocardial infarction